What is the appropriate management if the masses are pleural-based?

Management of Pleural-Based Masses

For pleural-based masses, CT-guided core needle biopsy is the recommended diagnostic approach when there is no pleural effusion or when thoracoscopy is not feasible, with thoracoscopy remaining the gold standard when technically possible. 1

Diagnostic Algorithm for Pleural-Based Masses

First-Line Approach: Thoracoscopy

• Thoracoscopy (medical thoracoscopy or VATS) is the gold standard with diagnostic yield >95% for pleural malignancies 1, 2
• Obtain multiple biopsies from different locations throughout the hemithorax
• Biopsies must be sufficiently deep to confirm invasion (distinguishes malignant mesothelioma from benign mesothelial proliferation)
• Allows simultaneous staging assessment and therapeutic intervention (talc pleurodesis if indicated)

Alternative Approach: Image-Guided Biopsy

When thoracoscopy is not feasible, CT-guided core needle biopsy of pleural-based masses is the reasonable alternative 1:

Specific indications for CT-guided biopsy:

• Nodular pleural thickening without effusion
• Poor performance status precluding general anesthesia
• Pleural symphysis (obliterated pleural space)
• Patient preference for less invasive approach

Technical considerations:

• Perform under local anesthesia
• CT-guided approach superior to blind pleural biopsy (87% vs 47% diagnostic yield) 2
• Ultrasound-guided biopsy achieves 94% diagnostic success in selected cases 2

Third-Line: Open Pleural Biopsy

• Reserved for patients with obliterated pleural space where neither thoracoscopy nor image-guided biopsy is possible 2
• Small muscle-sparing incision within intercostal space
• Thoracotomy rarely necessary for diagnosis

Critical Pathology Requirements

Adequate tissue is essential - biopsies must be:

• Sufficient size and depth for immunohistochemical staining
• Deep enough to confirm invasion
• Large enough for complete antibody panel testing (distinguishing mesothelioma from carcinoma/sarcoma)
• Adequate for BAP-1 and CDKN2A (p16) testing when standard staining insufficient 2

Important Clinical Pitfalls

Avoid Tumor Seeding

• Position biopsy tracts in line with potential future thoracotomy incisions 2
• Allows resection of biopsy tracts during definitive surgery
• Tumor spread along chest tracts is common and negatively impacts survival 2

Don't Rely on Cytology Alone

• Pleural fluid cytology has <33% sensitivity for mesothelioma 1
• Particularly poor for sarcomatoid and biphasic subtypes
• Cannot distinguish malignant from reactive mesothelial cells
• Cytology is screening only - histologic diagnosis always required for definitive management 1

Recognize Diagnostic Challenges

• Desmoplastic mesothelioma may evade diagnosis even with large biopsies (malignant cells rare within dense fibrotic stroma) 1
• ~10% of cases require specialized markers beyond standard staining 2

Special Consideration: Tuberculosis

Be aware that pleural-based masses can develop paradoxically during TB treatment in 34% of pleural TB cases 3. These are typically granulomatous inflammation, fibrous hyperplasia, or necrosis - not malignancy. Consider TB in appropriate clinical context (younger patients, loculated effusions, high ADA/LDH).